Literature DB >> 1845860

Peripheral nerve function in sepsis and multiple organ failure.

N J Witt1, D W Zochodne, C F Bolton, F Grand'Maison, G Wells, G B Young, W J Sibbald.   

Abstract

Forty-three patients who had sepsis and multiple organ failure (critical illness) were studied prospectively to determine the incidence and severity of peripheral nerve function and to correlate such function with a number of variables. Electrophysiologic studies indicated a primary axonal degeneration of motor and sensory fibers in 30 (70 percent). Fifteen (30 percent) had the clinical signs of difficulty in weaning from assisted ventilation, weakness of limb muscles, and reduced or absent deep tendon reflexes. Full recovery from the polyneuropathy occurred among the 23 (53 percent) who survived, except three who had a very severe polyneuropathy. A peripheral nerve function index, computed from electrophysiologic measurements, showed statistically significant (p less than 0.01) negative correlations with the time in the critical care unit, and the serum glucose value; the serum albumin level showed a positive correlation. Multiple regression analyses indicated all three factors accounted for 47 percent (r2 = 0.4678) of all potential variables. In a separate analysis, the nerve function index correlated with the amplitude of the diaphragm compound muscle action potential (p less than 0.01). The results were consistent with the polyneuropathy being due to the same mechanisms that are currently postulated to cause dysfunction in this syndrome of other organ systems (including the neuromuscular respiratory system).

Entities:  

Mesh:

Year:  1991        PMID: 1845860     DOI: 10.1378/chest.99.1.176

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  103 in total

1.  Evidence of neuromuscular dysfunction in the early stages of the systemic inflammatory response syndrome.

Authors:  C F Bolton
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

2.  Critical Illness Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

3.  Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both?

Authors:  Nicola Latronico
Journal:  Intensive Care Med       Date:  2003-09       Impact factor: 17.440

4.  Latent dystrophic myopathy revealed by unsuccessful weaning from mechanical ventilation.

Authors:  A Borgeat; G Pizzolato; J N Cox; P M Suter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

5.  Neurally adjusted ventilatory assist in patients with critical illness-associated polyneuromyopathy.

Authors:  Daniel Tuchscherer; Werner J Z'graggen; Christina Passath; Jukka Takala; Christer Sinderby; Lukas Brander
Journal:  Intensive Care Med       Date:  2011-11-03       Impact factor: 17.440

6.  Critical illness polyneuropathy and myopathy are common neuromuscular complications secondary to sepsis.

Authors:  Xiao-Ke Wang; Jie Zhu; Hong-Liang Zhang
Journal:  Neurol Sci       Date:  2012-02-04       Impact factor: 3.307

7.  Critical illness polyneuropathy after septic peritonitis in a boy with nephrotic syndrome.

Authors:  Eriko Kikuchi; Masaya Kubota; Koichi Kamei; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2010-03-16       Impact factor: 3.714

Review 8.  Intensive care unit-acquired weakness: implications for physical therapist management.

Authors:  Amy Nordon-Craft; Marc Moss; Dianna Quan; Margaret Schenkman
Journal:  Phys Ther       Date:  2012-01-26

Review 9.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

10.  Ventilatory strategies in patients with sepsis and respiratory failure.

Authors:  Dean R Hess; B Taylor Thompson
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.